A new treatment option is now available for the management of wet age-related macular degeneration (AMD). Brolucizumab is the first biologic agent and a new anti-vascular endothelial growth factor (anti-VEGF) designed specifically for intraocular use in humans.
Singapore researchers have developed a novel polygenic risk score (PRS) patterned specifically after Chinese children, improving its predictive performance for future high myopia (HM) in this population.
Isolation during the COVID-19 pandemic may lead to deterioration in comorbidities and mental health, according to two studies presented at the European Society of Endocrinology virtual conference (e-ECE 2021).
The increasing use of social media and online reviews has made it easier for patients to comment publicly—on Facebook and Google reviews, for instance—on the care they receive. Positive comments are heartening for any healthcare professional to read.
Low to moderate alcohol consumption may lower the likelihood of incident cataract that requires surgery, suggests a recent study of two large UK cohorts. Furthermore, this relationship is most evident for the consumption of polyphenol-rich wine.
The recurrent waves of the COVID-19 pandemic are having a significant impact on healthcare workers, and Medical Protection has called for more to be done globally to ensure that medical professionals have quick access to mental wellbeing support.
In the treatment of patients with neovascular age-related macular degeneration (nAMD), the biosimilar FYB201 appears to have similar efficacy, safety, and immunogenicity as ranibizumab, as shown in the results of a phase III study.